Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

a technology of gonadotropin and receptor antagonists, which is applied in the field of gonadotropin-releasing hormone receptor antagonists, can solve the problems of low bioavailability and adverse side effects of peptidic antagonists with low histamine release properties, and the clinical use of such antagonists, and achieve the effect of preventing or treating bone loss

Inactive Publication Date: 2006-01-26
NEUROCRINE BIOSCI INC
View PDF2 Cites 28 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent is about a new type of compound called gonadotropin-releasing hormone (GnRH) receptor antagonists and their use to treat a variety of medical conditions in men and women, including uterine fibroids, endometriosis, and precocious puberty. These compounds can also be used in combination with other drugs to treat bone-related diseases and disturbances of calcium and phosphate metabolism. The patent also describes methods for preparing and using these compounds, as well as pharmaceutical compositions containing them. Overall, this patent provides a new tool for treating a range of medical conditions and offers a potential for improved treatment outcomes.

Problems solved by technology

To date, some of the primary obstacles to the clinical use of such antagonists have been their relatively low bioavailability and adverse side effects caused by histamine release.
However, several peptidic antagonists with low histamine release properties have been reported, although they still must be delivered via sustained delivery routes (such as subcutaneous injection or intranasal spray) due to limited bioavailability.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
  • Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
  • Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

Examples

Experimental program
Comparison scheme
Effect test

example 1

SYNTHESIS OF 1-(2,6-DIFLUOROBENZYL)-2,6-DIMETHYL-3-BROMO-5-ETHOXYCARBONYL-4-PYRIDONE

[0119]

Step 1A Ethyl-3-(2.6-difluorobenzylamino)crotonate:

[0120] 2,6-Difluorobenzylamine (5.00 g, 35.0 mmol) was added to trimethyl orthoformate (88.0 mL) under N2. The resulting solution was stirred at room temperature for 20 minutes. Ethyl acetoacetate (4.5 mL, 35.0 mmol) was then added dropwise and the resulting mixture stirred for 24 hours (reaction progress monitored by LC / MS). The volatiles were removed under vacuum and the product solidified upon standing. Yield 7.88 g (30.9 mmol, 88%). 1H NMR (CDCl3, 300 MHz): 8.86 (br, 1H), 7.30-7.21 (m, 1H), 6.94-6.81 (m, 2H), 4.48 (s, 2H), 4.07 (q, J=6.9 Hz, 2H), 2.03 (s, 3H), 1.23 (t, J=6.9 Hz, 3H); LRMS m / z 256.1 (M++1).

Step 1B 1-(2.6-Difluorobenzyl)-2,6-dimethyl-3-ethoxycarbonyl-4-pyridone:

[0121] A mixture of ethyl-3-(2,6-difluorobenzylamino)crotonate (2.55 g, 10.0 mmol) and 2,2,6-trimethyl-1,3-dioxin-4-one (1.85 g, 13.0 mmol) in toluene (100 mL) was...

example 2

SYNTHESIS OF 1-(2,6-DIFLUOROBENZYL)-2,6-DIMETHYL-3-(2-FLUORO-3-METHOXYPHENYL)-5-[2-(2-PYRIDYL)ETHYLAMINOMETHYL]-4-PYRIDONE

[0123]

Step 2A 1-(2,6-Difluorobenzyl)-2.6-dimethyl-3-(2-fluoro-3-methoxyphenyl)-5-ethoxycarbonyl-4-pyridone

[0124] 1-(2,6-Difluorobenzyl)-2,6-dimethyl-3-bromo-5-ethoxycarbonyl-4-pyridone (1.5 g, 3.7 mmol) was evacuated in a pressure vessel with 2-fluoro-3-methoxyphenyl boronic acid (764 mg, 4.5 mmol) and tetrakis(triphenylphosphine) palladium (0) (428 mg, 370 μmol). A mixture of benzene / ethanol / 1,2-dimethoxyethane (74 ml in a 10 / 1 / 11 ratio) and barium hydroxide (saturated aqueous, about 0.5 M) was then added under vacuum, the vessel sealed under N2, and the reaction stirred at 90° C. for twelve hours, protected from light. The organic layer was concentrated and purified using flash silica chromatography (EtOAc / hexanes-1 / 4 to MeOH / CH2Cl2-2 / 98), with the product eluting as the third spot. The product was dried as an amber oil (1.12 g, 2.5 mmol, 68%). 1H NMR (CDCl3,...

example 3

SYNTHESIS OF 1-(2,6-DIFLUOROBENZYL)-2,6-DIMETHYL-3-(2-FLUORO-3-METHOXYPHENYL)-5-[2-(2-PYRIDYL)ETHYLAMINOMETHYL]-4-PYRIDONE

[0129]

Step 3A 1-(2.6-Difluorobenzyl)-2.6-dimethyl-3-(2-fluoro-3-methoxyphenyl)-5-[N-{2-(2-pyridyl)ethyl}-N-methylaminomethyl]-4-pyridone

[0130] Sodium triacetoxyborohydride (30 mg, 142 μmol) was added to a stirring solution of 1-(2,6-difluorobenzyl)-2,6-dimethyl-3-(2-fluoro-3-methoxybenzyl)-5-formyl-4-pyridone (20 mg, 50 μmol) and 2-(2-methylaminoethyl)pyridine (0.14 mL, 985 μmol) in dichloromethane (1 mL). The solution stirred overnight at r.t., MeOH (0.5 mL) was added and the solution concentrated, taken up in acetonitrile, filtered and purified using a Gilson Prep-HPLC system to give the product as a TFA salt in 34% yield.

[0131] The following compounds are synthesized according to above procedure.

TABLE 3No.R6R1R2N—MS (MH+)3-12-F-3-MeOPh2-PyCH2CH2NMe5223-22-F-3-MeOPhPhCH2NMe5073-32-F-3-MeOPh2-PyCH2NMe5083-42-F-3-MeOPh2-PyCH2NEt5223-52-F-3-MeOPh(2-PyCH2)2N58...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
Login to View More

Abstract

GnPRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein A, R1, R2, R3a, R3b, R4, R5, R6 R7 and n are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

Description

CROSS-REFERENCE TO RELATED APPLICATION [0001] This application is a divisional of U.S. application Ser. No. 10 / 211,978, filed Aug. 2, 2002, now allowed, which claims the benefit of U.S. Provisional Patent Application No. 60 / 309,937, filed Aug. 2, 2001, both of which applications are incorporated herein by reference in their entireties.STATEMENT OF GOVERNMENT INTEREST [0002] Partial funding of the work described herein was provided by the U.S. Government under Grant No. R43-HD38625 provided by the National Institute of Health. The U.S. Government may have certain rights in this invention.BACKGROUND OF THE INVENTION [0003] 1. Field of the Invention [0004] This invention relates generally to gonadotropin-releasing hormone (GnRH) receptor antagonists, and to methods of treating disorders by administration of such antagonists to a warm-blooded animal in need thereof. [0005] 2. Description of the Related Art [0006] Gonadotropin-releasing hormone (GnRH), also known as luteinizing hormone-r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/44A61K31/439A61K31/4418A61K31/443A61K31/4436A61K31/4439A61K31/444A61K31/455A61K31/4709A61K31/4725A61K31/496A61K31/506A61K31/52A61K31/5377A61P1/00A61P5/00A61P5/04A61P13/08A61P15/00A61P17/00A61P25/20A61P35/00A61P37/02A61P43/00C07D211/86C07D213/68C07D213/69C07D213/74C07D213/80C07D401/06C07D401/12C07D405/12C07D409/04C07D409/14C07D413/06C07D413/14C07D453/02C07D453/06C07D473/24
CPCC07D211/86C07D213/68C07D213/69C07D401/06C07D401/12C07D473/24C07D409/04C07D409/14C07D453/02C07D453/06C07D405/12A61P1/00A61P5/00A61P5/04A61P13/08A61P15/00A61P17/00A61P25/20A61P35/00A61P37/02A61P43/00
Inventor TUCCI, FABIOCONNORS, PATRICK J.ZHU, YUN-FEICHEN, CHEN
Owner NEUROCRINE BIOSCI INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com